GlassScriptPhysician profile
Elias A Feanny
NPI 1003869918
$6,387.95
in general payments reported to CMS, 2019-2025
39 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,849 · 2020: $966 · 2021: $130 · 2022: $124 · 2023: $651 · 2024: $973 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,299 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,298.99 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,166.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $877.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $589.21 | 2019-2025 | |
| Lilly USA, LLC | $572.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $336.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $309.92 | 2020-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $286.62 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $251.02 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.78 | 2021-2025 | |
| Amgen INC. | $188.66 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Corcept Therapeutics | $183.73 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $178.85 | 2019-2022 | |
| Dexcom, INC. | $131.25 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.33 | 2019-2025 | Ofev |
| Merck Sharp & Dohme LLC | $96.28 | 2019-2023 | Verquvo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Feanny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.